Can Baseline [18F]FDG PET/CT Predict Response to Immunotherapy After 6 Months and Overall Survival in Patients with Lung Cancer or Malignant Melanoma? A Multicenter Retrospective Study
Aim: To assess the role of baseline 18F-fluorodeoxyglucose ([18F]FDG)-positron emission tomography/computed tomography (PET/CT) in predicting response to immunotherapy after 6 months and overall survival (OS) in patients with lung cancer (LC) or malignant melanoma (MM). Materials and Methods: Data from a multicenter, retrospective study conducted between March and November 2021 were analyzed. Patients >18 years old with a confirmed diagnosis of LC or MM, who underwent a baseline [18F]FDG-PET/CT within 1-2 months before starting immunotherapy and had a follow-up of at least 12 months were included. PET scans were examined visually and semiquantitatively by physicians at peripheral centers. The metabolic tumor burden (number of lesions with [18F]FDG-uptake) and other parameters were recorded. Clinical response was assessed at 3 and 6 months after starting immunotherapy, and OS was calculated as the time elapsing between the PET scan and death or latest follow-up. Results: The study concerned 177 patients with LC and 101 with MM. Baseline PET/CT was positive in primary or local recurrent lesions in 78.5% and 9.9% of cases, in local/distant lymph nodes in 71.8% and 36.6%, in distant metastases in 58.8% and 84%, respectively, in LC and in MM patients. Among patients with LC, [18F]FDG-uptake in primary/recurrent lung lesions was more often associated with no clinical response to immunotherapy after 6 months than in cases without any tracer uptake. After a mean 21 months, 46.5% of patients with LC and 37.1% with MM had died. A significant correlation emerged between the site/number of [18F]FDG foci and death among patients with LC, but not among those with MM. Conclusions: In patients with LC who are candidates for immunotherapy, baseline [18F]FDG-PET/CT can help to predict response to this therapy after 6 months, and to identify those with a poor prognosis based on their metabolic parameters. For patients with MM, there was only a weak correlation between baseline PET/CT parameters, response to therapy, and survival.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Cancer biotherapy & radiopharmaceuticals - 38(2023), 4 vom: 10. Mai, Seite 256-267 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
0Z5B2CJX4D |
|---|
| Anmerkungen: |
Date Completed 15.05.2023 Date Revised 13.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1089/cbr.2022.0092 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356018202 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356018202 | ||
| 003 | DE-627 | ||
| 005 | 20231227131225.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1089/cbr.2022.0092 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1225.xml |
| 035 | |a (DE-627)NLM356018202 | ||
| 035 | |a (NLM)37098169 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bianchi, Andrea |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Can Baseline [18F]FDG PET/CT Predict Response to Immunotherapy After 6 Months and Overall Survival in Patients with Lung Cancer or Malignant Melanoma? A Multicenter Retrospective Study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.05.2023 | ||
| 500 | |a Date Revised 13.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aim: To assess the role of baseline 18F-fluorodeoxyglucose ([18F]FDG)-positron emission tomography/computed tomography (PET/CT) in predicting response to immunotherapy after 6 months and overall survival (OS) in patients with lung cancer (LC) or malignant melanoma (MM). Materials and Methods: Data from a multicenter, retrospective study conducted between March and November 2021 were analyzed. Patients >18 years old with a confirmed diagnosis of LC or MM, who underwent a baseline [18F]FDG-PET/CT within 1-2 months before starting immunotherapy and had a follow-up of at least 12 months were included. PET scans were examined visually and semiquantitatively by physicians at peripheral centers. The metabolic tumor burden (number of lesions with [18F]FDG-uptake) and other parameters were recorded. Clinical response was assessed at 3 and 6 months after starting immunotherapy, and OS was calculated as the time elapsing between the PET scan and death or latest follow-up. Results: The study concerned 177 patients with LC and 101 with MM. Baseline PET/CT was positive in primary or local recurrent lesions in 78.5% and 9.9% of cases, in local/distant lymph nodes in 71.8% and 36.6%, in distant metastases in 58.8% and 84%, respectively, in LC and in MM patients. Among patients with LC, [18F]FDG-uptake in primary/recurrent lung lesions was more often associated with no clinical response to immunotherapy after 6 months than in cases without any tracer uptake. After a mean 21 months, 46.5% of patients with LC and 37.1% with MM had died. A significant correlation emerged between the site/number of [18F]FDG foci and death among patients with LC, but not among those with MM. Conclusions: In patients with LC who are candidates for immunotherapy, baseline [18F]FDG-PET/CT can help to predict response to this therapy after 6 months, and to identify those with a poor prognosis based on their metabolic parameters. For patients with MM, there was only a weak correlation between baseline PET/CT parameters, response to therapy, and survival | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a FDG PET/CT | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a lung cancer | |
| 650 | 4 | |a malignant melanoma | |
| 650 | 4 | |a prognosis | |
| 650 | 7 | |a Fluorodeoxyglucose F18 |2 NLM | |
| 650 | 7 | |a 0Z5B2CJX4D |2 NLM | |
| 700 | 1 | |a De Rimini, Maria Luisa |e verfasserin |4 aut | |
| 700 | 1 | |a Sciuto, Rosa |e verfasserin |4 aut | |
| 700 | 1 | |a Annovazzi, Alessio |e verfasserin |4 aut | |
| 700 | 1 | |a Di Traglia, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Bauckneht, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Lanfranchi, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Morbelli, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Nappi, Anna Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrari, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Rubini, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Panareo, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Urso, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Bartolomei, Mirco |e verfasserin |4 aut | |
| 700 | 1 | |a D'Arienzo, Davide |e verfasserin |4 aut | |
| 700 | 1 | |a Valente, Tullio |e verfasserin |4 aut | |
| 700 | 1 | |a Rossetti, Virginia |e verfasserin |4 aut | |
| 700 | 1 | |a Caroli, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Matteucci, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Aricò, Demetrio |e verfasserin |4 aut | |
| 700 | 1 | |a Bombaci, Michelangelo |e verfasserin |4 aut | |
| 700 | 1 | |a Caponnetto, Domenica |e verfasserin |4 aut | |
| 700 | 1 | |a Bertagna, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Albano, Domenico |e verfasserin |4 aut | |
| 700 | 1 | |a Dondi, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Gusella, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Spimpolo, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Carriere, Cinzia |e verfasserin |4 aut | |
| 700 | 1 | |a Balma, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Buschiazzo, Ambra |e verfasserin |4 aut | |
| 700 | 1 | |a Gallicchio, Rosj |e verfasserin |4 aut | |
| 700 | 1 | |a Storto, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Ruffini, Livia |e verfasserin |4 aut | |
| 700 | 1 | |a Scarlattei, Maura |e verfasserin |4 aut | |
| 700 | 1 | |a Baldari, Giorgio |e verfasserin |4 aut | |
| 700 | 1 | |a Cervino, Anna Rita |e verfasserin |4 aut | |
| 700 | 1 | |a Cuppari, Lea |e verfasserin |4 aut | |
| 700 | 1 | |a Burei, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Trifirò, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Brugola, Elisabetta |e verfasserin |4 aut | |
| 700 | 1 | |a Zanini, Carolina Arianna |e verfasserin |4 aut | |
| 700 | 1 | |a Alessi, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Fuoco, Valentina |e verfasserin |4 aut | |
| 700 | 1 | |a Seregni, Ettore |e verfasserin |4 aut | |
| 700 | 1 | |a Deandreis, Désirée |e verfasserin |4 aut | |
| 700 | 1 | |a Liberini, Virginia |e verfasserin |4 aut | |
| 700 | 1 | |a Moreci, Antonino Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Ialuna, Salvatore |e verfasserin |4 aut | |
| 700 | 1 | |a Pulizzi, Sabina |e verfasserin |4 aut | |
| 700 | 1 | |a Evangelista, Laura |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer biotherapy & radiopharmaceuticals |d 1996 |g 38(2023), 4 vom: 10. Mai, Seite 256-267 |w (DE-627)NLM095459251 |x 1557-8852 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2023 |g number:4 |g day:10 |g month:05 |g pages:256-267 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1089/cbr.2022.0092 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2023 |e 4 |b 10 |c 05 |h 256-267 | ||